FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 15, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by […]
REZUROCK™ (belumosudil) Tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson
CARY, N.C., JULY 30, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced […]
A Letter to Our Biopharma Clients About Organizational Changes
Valued Biopharma Partner, At Biologics by McKesson, we know that your complex, personalized therapies require customized support tailored to your […]
A Letter to Our Customers from Our New General Manager, Brandon Tom
Valued Customers, As the new vice president and general manager of Biologics by McKesson, let me start by saying I am truly thrilled to lead this wonderful […]
Our Response to COVID-19 from the President of McKesson Life Sciences
Dear Customer, COVID-19 (coronavirus) is top of mind for us at McKesson Life Sciences and it is a situation that […]